Comorbidity, Metastases, And Survival In Women With Metastatic Breast Cancer (Mbc) Receiving Her2-Targeted Agents (H2ts).

e11574 Background: Little information on survival is available for subgroups of HER2+ mBC patients. Study objectives were to compare clinical histories, progression, and survival of mBC patients treated with H2Ts, by de novo vs recurrent status , ER+ status, and age. Methods: Women ≥ 18 years with Stage IV mBC (index) during 2008-2012 and treated with H2Ts were selected from a large claims database and followed until death or end of data. Patients were stratified by ER+ status, de novo (≤90 days between initial BC diagnosis and index) vs recurrent (u003e90 days between initial BC diagnosis and index), and ages 18-44, 45-64, or 65+. Relative risk of progression and death were evaluated among the subset of patients with mortality data. Results: Of 2,629 eligible patients, 52% were ER+, 37% de novo, 15% 18-44, 69% 45-64 and 16% 65+. Median follow-up was longer for ER+ vs ER-, de novo vs recurrent, and decreased with age. Baseline comorbid conditions were lower for ER+ vs ER-, higher for de novo vs recurrent and ...